 East Setauket, March 02, 2021 GLOBE NEWSWIRE -- Lixte Biotechnology Holdings, Inc. Nasdaq: LIXT, a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, today announced that it has closed a registered direct offering with certain institutional and accredited investors for 4.19 million of common stock. The Company issued a total of 1,133,102 shares of common stock, at a purchase price of 3.70 per share. 